For the Inventor, By the Inventor

Enter assignee name

Dublin, OH, United States of America

Navidea Biopharmaceuticals, Inc.

USPTO Granted Patents = 14

EPO Patents = 1

Trademarks = 7

Forward Citations = 29

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

David A Ralph (9 out of 9 patents)

Jeffrey Scott Arnold (6 out of 6 patents)

Frederick O Cope (3 out of 4 patents)

4. Gerald Ross Magneson (2 out of 2 patents)

5. Richard Cushman Orahood (2 out of 3 patents)

6. Ylva Gravenfors (1 out of 3 patents)

7. Catrin Jonasson (1 out of 2 patents)

8. Jonas Malmstrom (1 out of 4 patents)

9. Gunnar Nordvall (1 out of 20 patents)

10. David Pyring (1 out of 3 patents)

11. Can Slivo (1 out of 5 patents)

12. Daniel Sohn (1 out of 12 patents)

13. Peter Strom (1 out of 2 patents)

14. Gregg J Chapman (1 out of 3 patents)

15. David Wensbo (1 out of 10 patents)

14 patents: Sort by Forward Citations

1. 12404349 - Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers (2025-09-02),

2. 12297222 - CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker (2025-05-13),

3. 12178829 - Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking (2024-12-31),

4. 12006339 - CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker (2024-06-11),

5. 12005122 - Compounds and methods for diagnosis and treatment of viral infections (2024-06-11),

6. 11859023 - Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof (2024-01-02),

7. 11833170 - Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking (2023-12-05),

8. 11590236 - Compositions and methods for altering macrophage phenotype (2023-02-28),

9. 11369680 - Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same (2022-06-28),

10. 11007272 - Compounds and methods for diagnosis and treatment of viral infections (2021-05-18),

11. 9439985 - Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran (2016-09-13),

12. 8957215 - Heteroaryl substituted benzothiazoles (2015-02-17),

13. 8545808 - Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran (2013-10-01),

14. 8227766 - Hand-held probe for intra-operative detection of fluorescence labeled compounds and antibodies (2012-07-24),

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. They are dedicated to advancing precision medicine by providing innovative imaging technologies for improved diagnosis and treatment of various diseases, including cancer and autoimmune disorders.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

14 Patents

#10 in Dublin, OH

#895 in Ohio

#21,655 in US

#40,959 in the World

Dublin, OH, United States of America

Navidea Biopharmaceuticals, Inc.

Forward Citations = 29

15 inventors:

David A Ralph (9 out of 9 patents)

Jeffrey Scott Arnold (6 out of 6 patents)

Frederick O Cope (3 out of 4 patents)

4. Gerald Ross Magneson (2 out of 2 patents)

5. Richard Cushman Orahood (2 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…